XFOR - X4 Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
XFOR price evolution
XFOR
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $147.22 | $60.49 | $99.22 | $131.58 |
| Short term investments | $21.54 | $20.38 | $15 | $10.1 |
| Net receivables | $0.85 | $0.7 | $0.56 | $0.39 |
| Inventory | $0.83 | |||
| Total current assets | $175.42 | $87.33 | $122.08 | $147.87 |
| Long term investments | ||||
| Property, plant & equipment | $5.68 | $6.01 | $6.39 | $6.83 |
| Goodwill & intangible assets | $27.73 | $17.35 | $17.35 | $17.35 |
| Total noncurrent assets | $35.2 | $24.85 | $25.18 | $25.42 |
| Total investments | $21.54 | $20.38 | $15 | $10.1 |
| Total assets | $210.61 | $112.18 | $147.26 | $173.29 |
| Current liabilities | ||||
| Accounts payable | $7.99 | $8.94 | $8.95 | $8.13 |
| Deferred revenue | ||||
| Short long term debt | $1.17 | $1.13 | $1.1 | $1.12 |
| Total current liabilities | $28.9 | $23.54 | $22.86 | $25.43 |
| Long term debt | $77.06 | $57.14 | $57.18 | $57.17 |
| Total noncurrent liabilities | $87.26 | $87.61 | $73.3 | $80.27 |
| Total debt | $78.23 | $58.27 | $58.28 | $58.29 |
| Total liabilities | $116.16 | $111.15 | $96.16 | $105.7 |
| Shareholders' equity | ||||
| Retained earnings | -$438.84 | -$529.67 | -$477.9 | -$458.77 |
| Other shareholder equity | -$0.16 | -$0.15 | -$0.12 | -$0.12 |
| Total shareholder equity | $94.45 | $1.04 | $51.1 | $67.59 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.22 | $121.72 | $81.79 | $78.71 |
| Short term investments | $15 | |||
| Net receivables | $0.56 | $1.15 | $0.75 | $0.92 |
| Inventory | ||||
| Total current assets | $122.08 | $128.68 | $87.88 | $83.31 |
| Long term investments | ||||
| Property, plant & equipment | $6.39 | $8.33 | $10.22 | $9.2 |
| Goodwill & intangible assets | $17.35 | $17.35 | $17.35 | $27.11 |
| Total noncurrent assets | $25.18 | $26.91 | $29.3 | $39.56 |
| Total investments | $15 | |||
| Total assets | $147.26 | $155.59 | $117.18 | $122.87 |
| Current liabilities | ||||
| Accounts payable | $8.95 | $7.78 | $4.28 | $3.14 |
| Deferred revenue | ||||
| Short long term debt | $1.1 | $2.51 | $1.87 | $0.79 |
| Total current liabilities | $22.86 | $22.32 | $14.02 | $11.95 |
| Long term debt | $57.18 | $35.91 | $37.91 | $37.66 |
| Total noncurrent liabilities | $73.3 | $59.21 | $38.74 | $38.12 |
| Total debt | $58.28 | $38.42 | $39.78 | $38.45 |
| Total liabilities | $96.16 | $81.53 | $52.76 | $50.07 |
| Shareholders' equity | ||||
| Retained earnings | -$477.9 | -$376.74 | -$282.87 | -$194.18 |
| Other shareholder equity | -$0.12 | -$0.12 | -$0.12 | -$0.12 |
| Total shareholder equity | $51.1 | $74.05 | $64.41 | $72.8 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.56 | |||
| Cost of revenue | $0.27 | |||
| Gross Profit | $0.29 | |||
| Operating activities | ||||
| Research & development | $20.91 | $19.85 | $15.27 | $19.08 |
| Selling, general & administrative | $13.28 | $17.43 | $9.93 | $8.13 |
| Total operating expenses | -$70.81 | $37.29 | $25.2 | $27.21 |
| Operating income | $71.1 | -$37.29 | -$25.2 | -$27.21 |
| Income from continuing operations | ||||
| EBIT | $93.03 | -$49.87 | -$17.21 | -$0.65 |
| Income tax expense | $0.02 | $0.02 | $0.03 | $0.03 |
| Interest expense | $2.18 | $1.87 | $1.89 | $1.63 |
| Net income | ||||
| Net income | $90.83 | -$51.77 | -$19.13 | -$2.31 |
| Income (for common shares) | $90.83 | -$51.77 | -$19.13 | -$2.31 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3 | |||
| Cost of revenue | ||||
| Gross Profit | $3 | |||
| Operating activities | ||||
| Research & development | $72.02 | $61.06 | $50.65 | $41.93 |
| Selling, general & administrative | $35.51 | $27.02 | $24.7 | $20.94 |
| Total operating expenses | $107.52 | $87.57 | $85.11 | $62.87 |
| Operating income | -$107.52 | -$87.57 | -$85.11 | -$59.87 |
| Income from continuing operations | ||||
| EBIT | -$95.31 | -$89.85 | -$85.04 | -$59.3 |
| Income tax expense | $0.08 | $0.03 | $0.02 | $0.15 |
| Interest expense | $5.78 | $3.99 | $3.64 | $2.69 |
| Net income | ||||
| Net income | -$101.17 | -$93.87 | -$88.7 | -$62.13 |
| Income (for common shares) | -$101.17 | -$96.41 | -$102.64 | -$62.13 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $90.83 | -$51.77 | -$19.13 | -$2.31 |
| Operating activities | ||||
| Depreciation | $0.59 | $0.45 | $0.47 | $0.5 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.43 | $1.74 | $2.54 | $2.36 |
| Total cash flows from operations | -$30.28 | -$33.6 | -$27.75 | -$20.83 |
| Investing activities | ||||
| Capital expenditures | -$7.13 | -$0.06 | -$0.04 | -$0.01 |
| Investments | $104 | -$5.26 | -$4.8 | -$5.15 |
| Total cash flows from investing | $96.86 | -$5.32 | -$4.83 | -$5.16 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.16 | $0.1 | -$0.28 | |
| Net borrowings | $20 | $0.63 | $21.49 | |
| Total cash flows from financing | $20.16 | $0.1 | $21.2 | |
| Effect of exchange rate | -$0.02 | -$0.06 | $0.13 | -$0.07 |
| Change in cash and equivalents | $86.73 | -$38.98 | -$32.36 | -$4.85 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$101.17 | -$93.87 | -$88.7 | -$62.13 |
| Operating activities | ||||
| Depreciation | $2 | $1.99 | $1.89 | $1.23 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $8.69 | $5.2 | $6.18 | $5.43 |
| Total cash flows from operations | -$96.51 | -$77.1 | -$70.91 | -$58.82 |
| Investing activities | ||||
| Capital expenditures | -$0.06 | -$0.1 | -$0.61 | -$1.36 |
| Investments | -$14.82 | |||
| Total cash flows from investing | -$14.88 | -$0.1 | -$0.61 | -$1.36 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $68.71 | $118.04 | $74.25 | $0.28 |
| Net borrowings | $20.44 | -$0.8 | $12.39 | |
| Total cash flows from financing | $88.52 | $117.23 | $74.25 | $12.39 |
| Effect of exchange rate | $0.1 | -$0.1 | -$0.32 | $0.4 |
| Change in cash and equivalents | -$22.78 | $39.92 | $2.41 | -$47.38 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $563.00K |
|---|---|
| EBITDA | $27.30M |
| EBIT | $25.30M |
| Net Income | $17.63M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | 10.96% |
| ROE | 32.93% |
| Debt/Equity | 1.88 |
|---|---|
| Net debt/EBITDA | -1.14 |
| Current ratio | 6.07 |
| Quick ratio | 6.04 |